CLOs on the Move


 
Kadmon is a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. We are developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. We leverage our multi-disciplinary research and clinical development team members, who prior to joining Kadmon had brought more than 15 drugs to market, to identify and pursue a diverse portfolio of novel product candidates, both through in-licensing products and employing our small molecule and biologics platforms. We utilize our advanced understanding of the molecular mechanisms of disease to ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.kadmon.com
  • 450 East 29th Street
    New York, NY USA 10016
  • Phone: 212.308.6000

Executives

Name Title Contact Details
Steven Gordon
Executive Vice President, General Counsel, Chief Administrative, Compliance and Legal Officer, and Corporate Secretary Profile
Gregory Moss
Executive Vice President, General Counsel and Corporate Secretary Profile
Gregory Moss
Executive Vice President, General Counsel and Corporate Secretary Profile

Similar Companies

Bellus Health

BELLUS Health is a clinical stage biotechnology company developing novel therapeutics for the treatment of chronic cough and other chronic disorders triggered by hypersensitization.

XtalPi

XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform.

Nutra-C

Nutra-C is a Laurel, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Capital Technology Information Services

Capital Technology Information Services is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Redpin Therapeutics

Welcome to Redpin Therapeutics. We are a privately held, preclinical stage gene therapy company based in New York City. We are developing a proprietary chemogenetics platform for targeted cell therapies that address currently intractable diseases of the nervous system. Our approach integrates powerful principles from synthetic biology, gene therapy, and traditional pharmacotherapy.